Artificial intelligence is rapidly transforming the pharmaceutical industry, and Pricing & Market Access (P&MA) is no exception. While many organizations have started exploring AI through pilot initiatives, few have fully integrated it into how evidence is generated, value is communicated, and access strategies are developed.
Watch our webinar recording to learn how P&MA organizations can move beyond experimentation and translate AI ambitions into measurable business impact. Drawing on industry benchmarking and practical experience, our experts share how leading companies are embedding AI into their operating models, decision-making processes, and value creation strategies.
This session covers:
- Why AI is becoming a strategic priority for P&MA and what is driving urgency
- How leading organizations are progressing along the AI maturity curve
- Which use cases are reshaping evidence generation, launch planning, and stakeholder engagement
- Why deep P&MA and technical expertise are essential to navigating use-case opportunities and build/buy decisions
- What it means to redesign processes and operating models to be AI-enabled
- How to approach data, technology, and organizational ownership to enable scale
